Indication for Venous Ports in Oncology Comparing Different Experiences in Europe

Horattas M.C. , Trupiano J. , Hopkins S. , Pasini D. , Martino C. , Murty A. : Changing concepts in long-term central venous access: Catheter selection and cost savings. Am J Infect Control, 29: 32–40, 2001.

Ballarini C. , Intra M. , Pisani Ceretti A. , Cordovana A. , Pagani M. , Farina G. , Perrone S. , Tomirotti M. , Scanni A. , Spina G.P. : Complications of subcutaneous infusion port in the general oncology population. Oncology, 56: 97–102, 1999.

Biffi R. , Corrado F. , de Braud F. , de Lucia F. , Scarpa D. , Testori A. , Orsi F. , Bellomi M. , Mauri S. , Aapro M. , Andreoni B. : Long-term, totally implantable central venous access ports connected to a Groshong catheter for chemotherapy of solid tumours: experience from 178 cases using a single type of device. Eur J Cancer, 33: 1190–1194, 1997.

Bertoglio S. , Di Somma C. , Meszaros P. , Gipponi M. , Cafiero F. , Percivale P. : Long-term femoral vein central venous access in cancer patients. Eur J Surg Oncol, 22: 162–165, 1996.

Aldrighetti L. , Caterini R. , Ronzoni M. , Jannello A. , Ferla G. : Role of totally implantable systems for long-term vascular access in the treatment of the neoplastic patient. Minerva Chir, 50: 447–454, 1995.

Biffi R. , de Braud F. , Orsi F. , Pozzi S. , Mauri S. , Goldhirsch A. , Nole F. , Andreoni B. : Totally implantable central venous access ports for long-term chemotherapy. A prospective study analyzing complications and costs of 333 devices with a minimum follow-up of 180 days. Ann Oncol, 9: 767–773, 1998.

Freytes C.O. : Indications and complications of intravenous devices for chemotherapy. Curr Opin Oncol, 12: 303–307, 2000.

Alexander H.R. : Vascular access and specialized techniques of drug delivery. In: Cancer: principles and practice of oncology, De Vita V.T. Jr ., Hellman S. , Rosenberg S.A. (Eds), pp 725–734, Lippincott-Raven Publishers, Philadelphia, 1997.

Biffi R. , Martinelli G. , Pozzi S. , Cinieri S. , Cocorocchio E. , Peccatori F. , Ferrucci P.F. , Pistorio R. , Andreoni B. : Totally implantable central venous access ports for high-dose chemotherapy administration and autologous stem cell trans plantation: analysis of overall and septic complications in 68 cases using a single type of device. Bone Marrow Transplant, 24: 89–93, 1999.

deGramont A. , Bosset J. , Milan C. , Rougier P. , Bouché O. , Etienne P. , Morvan F. , Louvet C. , Guillot E. , Bedenne L. : Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French Intergroup study. J Clin Oncol, 15: 808–815, 1997.

deGramont A. , Figer A. , Seymour M. , Homerin M. , Hmissi A. , Cassidy J. , Boni C. , Cortes-Funes H. , Cervantes A. , Freyer G. , Papamichael D. , Le Bail N. , Louvet C. , Hendler D. , deBraud F. , Wilson C. , Marvan F. , Bonetti A. : Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol, 18: 2938–2947, 2000.

Saltz L.B. , Cox J.V. , Blanke C. , Lee S.R. , Fehrenbacher L. , Moore M.J. , Maroun J.A. , Ackland S.P. , Locker P.K. , Pirotta N. , Elfring G.L. , Miller L.L. for the Irinotecan Study Group: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med, 343: 905–914, 2000.

Lombardi D. , Magri M.D. , Crivellari D. , Spazzapan S. , Paolello C. , De Cicco M. , Di Lauro V. , Scuderi C. , Veronesi A. : Combination chemotherapy with navelbine and continuous infusion of 5-fluorouracil in metastatic, chemotherapy refractory breast cancer. Ann Oncol, 11: 1041–1043, 2000.

Garufi C. , Dogliotti L. , D'Attino R.M. , Tampellini M. , Aschelter A.M. , Pugliese P. , Perrone M. , Nistico C. , Comos S. , Terzoli E. : Irinotecan and chronomodulated infusion of 5-fluorouracil and folinic acid in the treatment of patients with advanced colorectal carcinoma: a phase I study. Cancer, 91: 712–720, 2001.

Bow E.J. , Kilpatrick M.G. , Clinch J.J. : Totally implantable venous access ports systems for patients receiving chemotherapy for solid tissue malignancies. A randomized controlled clinical trial examining the safety, efficacy, costs, and impact on quality of life. J Clin Oncol, 17: 1267, 1999.